Enzymatically Released Aryl Diazonium Ions

Technology #ua17-088

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Jie He
graduate student, 26 Chemistry & Biochemistry
Bereketab Mehari
Graduate assistant, CBC
Lindsay Guzman
Graduate Assistant, Chemistry & Biochemistry
John Jewett
Assistant Professor, Chemistry & Biochemistry
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Title: Enzymatically Released Aryl Diazonium Ions

 

Invention: The invention is the discovery of triazebutadienes that rapidly release aryl diazonium ions at neutral pH with a half-life of approximately one minute.

 

Background: In 2015, the global protein therapeutics market grew to nearly $174.7 billion due to trends in targeted therapies that resulted in fewer side effects. Monoclonal antibodies and biologics are the largest portion of newer medications in development, leaving room for the development of novel pathways and techniques to fuel the creation of new therapies. 

Applications:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic assay companies
  • Research centers
  • Academic laboratories

 

Advantages:

  • Can be time-released by protecting triazebutadienes with stable, enzymatically releasable groups

 

Licensing Manager:

Paul Eynott

PaulE@tla.arizona.edu

(520) 471-2687